PuraPharm Corporation Limited (1498.HK)
HKD 0.49
(-1.01%)
HKD 0.49
(-1.01%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -66.04 Million HKD | 20.03% |
| 2022 | -64.5 Million HKD | -466.1% |
| 2021 | 17.61 Million HKD | 461.17% |
| 2020 | -4.87 Million HKD | 92.04% |
| 2019 | -61.24 Million HKD | -762.48% |
| 2018 | 9.24 Million HKD | 420.78% |
| 2017 | -2.88 Million HKD | -107.13% |
| 2016 | 40.42 Million HKD | -12.39% |
| 2015 | 46.14 Million HKD | -11.11% |
| 2014 | 51.9 Million HKD | 38.18% |
| 2013 | 37.56 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.98 Million HKD | 78.63% |
| 2023 Q2 | -18.9 Million HKD | 65.19% |
| 2023 FY | -51.58 Million HKD | 20.03% |
| 2023 Q4 | -32.68 Million HKD | -72.91% |
| 2022 FY | -64.5 Million HKD | -466.1% |
| 2022 Q4 | -54.3 Million HKD | -432.41% |
| 2022 Q2 | -10.19 Million HKD | -1121.44% |
| 2021 Q2 | 18.45 Million HKD | 184.9% |
| 2021 FY | 17.61 Million HKD | 461.17% |
| 2021 Q4 | -835 Thousand HKD | -104.53% |
| 2020 Q2 | -11.35 Million HKD | 62.7% |
| 2020 FY | -4.87 Million HKD | 92.04% |
| 2020 Q4 | 6.47 Million HKD | 157.04% |
| 2019 FY | -61.24 Million HKD | -762.48% |
| 2019 Q2 | -30.8 Million HKD | -159.43% |
| 2019 Q4 | -30.43 Million HKD | 1.19% |
| 2018 FY | 9.24 Million HKD | 420.78% |
| 2018 Q4 | -11.87 Million HKD | -156.23% |
| 2018 Q2 | 21.12 Million HKD | 221.7% |
| 2017 Q2 | 14.47 Million HKD | -52.68% |
| 2017 Q4 | -17.35 Million HKD | -219.91% |
| 2017 FY | -2.88 Million HKD | -107.13% |
| 2016 FY | 40.42 Million HKD | -12.39% |
| 2016 Q2 | 9.84 Million HKD | -79.08% |
| 2016 Q4 | 30.58 Million HKD | 210.76% |
| 2015 Q2 | -904 Thousand HKD | -102.41% |
| 2015 FY | 46.14 Million HKD | -11.11% |
| 2015 Q4 | 47.04 Million HKD | 5304.2% |
| 2014 Q4 | 37.52 Million HKD | 160.97% |
| 2014 FY | 51.9 Million HKD | 38.18% |
| 2014 Q2 | 14.38 Million HKD | 3.92% |
| 2013 FY | 37.56 Million HKD | 0.0% |
| 2013 Q4 | 13.83 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 146.182% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 102.48% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | -709.189% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 261.561% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | -26.566% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | 283.247% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 121.283% |
| Tongfang Kontafarma Holdings Limited | - HKD | Infinity% |
| SSY Group Limited | 1.63 Billion HKD | 104.03% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 137.913% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 119.826% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 100.544% |